Senactiv / ActiGin (Panax notoginseng & Rosa roxburghii)

Senactiv (formerly ActiGin) is a patented NuLiv Science blend of purified Panax notoginseng and Rosa roxburghii extracts (active saponins ginsenoside Rg1 and Rb1), marketed for exercise: muscle glycogen replenishment, reduced exercise-induced inflammation/muscle damage, and senescent-cell clearance ('senolytic'). The human evidence is a small cluster of double-blind crossover trials (n approximately 12-16 young trained men) from a single research group and sponsored by the manufacturer, using muscle-biopsy surrogate endpoints (notably ~2.7-fold greater post-exercise glycogen resynthesis, plus citrate synthase and IL-6/CK/MDA markers); a separate trial of the isolated saponin Rg1 (5 mg, not the Senactiv blend) reported ~20% longer time-to-exhaustion, so that endurance figure should not be attributed to the blend itself. The senolytic/anti-aging claims rest on mechanistic and animal data. No independent replication. This directly parallels our AstraGin entry (same maker, same low grade). Low evidence. Theoretical bleeding/antiplatelet risk from the Panax notoginseng component; caution with anticoagulants and before surgery.

Limited clinical evidence. A few tiny, single-lab, manufacturer-funded trials with surrogate endpoints and no independent replication (parallels AstraGin)